Detalhe da pesquisa
1.
Redefining ITT cortisol thresholds on Abbott platforms to prevent misdiagnosis of adrenal insufficiency.
Clin Endocrinol (Oxf);
2024 May 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38798198
2.
Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
Diabetes Obes Metab;
26(4): 1479-1491, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38229453
3.
100 years of glucagon and 100 more.
Diabetologia;
66(8): 1378-1394, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37367959
4.
The postprandial secretion of peptide YY1-36 and 3-36 in obesity is differentially increased after gastric bypass versus sleeve gastrectomy.
Clin Endocrinol (Oxf);
99(3): 272-284, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36345253
5.
Sleeve gastrectomy causes weight-loss independent improvements in hepatic steatosis.
Liver Int;
43(9): 1890-1900, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37208943
6.
Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single-blind placebo-controlled study.
Diabetes Obes Metab;
25(6): 1731-1739, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36811311
7.
The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis.
Int J Obes (Lond);
46(11): 1948-1959, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36123404
8.
Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study.
Am J Physiol Endocrinol Metab;
320(4): E671-E679, 2021 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33459181
9.
Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial.
Diabetes Obes Metab;
23(7): 1471-1483, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33606914
10.
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome.
Curr Diab Rep;
20(7): 26, 2020 05 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32436022
11.
Commentary on "The road to reliable peptide assays is paved with good guidelines".
Clin Endocrinol (Oxf);
98(6): 763-765, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36915993
12.
The effects of kisspeptin on food intake in women with overweight or obesity.
Diabetes Obes Metab;
25(8): 2393-2397, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37039248
13.
Tirzepatide and the new era of twincretins for diabetes.
Lancet;
398(10295): 95-97, 2021 07 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34186023
14.
Surpassing insulin glargine in type 2 diabetes with tirzepatide.
Lancet;
398(10313): 1779-1781, 2021 11 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34672968
15.
The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.
Diabetes Obes Metab;
24(7): 1385-1389, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35293117
16.
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Peptides;
176: 171219, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38615717
17.
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence.
J Endocrinol;
261(3)2024 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38579751
18.
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action.
Trends Cardiovasc Med;
2024 Mar 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38555029
19.
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status.
Endocr Rev;
2024 May 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38795365
20.
Quantifying the variability in the assessment of reproductive hormone levels.
Fertil Steril;
121(2): 334-345, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37977226